Últimas noticias sobre Aadi Bioscience (NASDAQ:AADI) Bolsa

Aadi Bioscience

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience Inc

Aadi Bioscience, Inc. 2024 Q2 - Results - Earnings Call Presentation

Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript

Aadi plunges 36% as phase 2 trial for solid tumors asset unlikely to meet goal

Aadi Bioscience (AADI – Research Report) received a Hold rating and price target from TD Cowen analyst Tara Bancroft yesterday. The company's share...

TD Cowen downgrades Aadi Bioscience (AADI) to a Hold

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on AADI stock, giving a Hold rating yesterday. Robert Burns has given his ...

Aadi Bioscience: Hold Rating Amidst Trial Discontinuation and Limited Growth Prospects

Aadi Bioscience cut to hold at Jefferies following Fyarro failure in solid tumors

Aadi Bioscience (AADI) has provided an update. Loretta Itri, M.D., is stepping down as Chief Medical Officer but will receive a generous severance ...

Aadi Bioscience Executives Transition with Continued Roles

In a report released today, Joseph Catanzaro from Piper Sandler downgraded Aadi Bioscience (AADI – Research Report) to a Hold, with a price target ...

Hold Rating for Aadi Bioscience Amid Clinical Setbacks and Modest Revenue Projections

Aadi Bioscience downgraded to Neutral, shares fall

Aadi Bioscience ( ($AADI) ) has provided an update. Aadi Bioscience, Inc. has initiated a retention bonus program to incentivize its key employees,...

Aadi Bioscience Launches Executive Retention Bonus Program

AADI

Earnings

Press Releases

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update

Small Cap

Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Aadi Bioscience to Participate in the Jefferies Healthcare Conference

Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update

Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Celularity

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Elicio Therapeutics

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fortress Biotech

Gain Therapeutics

HOOKIPA Pharma

Immix Biopharma

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kezar Life Sciences

Lantern Pharma

Mural Oncology

Passage Bio

Rallybio

Shattuck Labs

Syros Pharmaceuticals, Inc. - Common Stock

Comments

Aadi Bioscience

Noticias

Últimas noticias sobre Aadi Bioscience (NASDAQ:AADI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL